Aytu BioPharma to be acquired by Rosemont for $2.70 a share
Aytu BioPharma disclosed an agreement to be bought by Rosemont Pharmaceuticals in a tender offer at $2.70 per share in cash, with a follow-on merger; the stock closed up 46% on about 77 times its average volume.
What happened
Aytu BioPharma, Inc., a Delaware-incorporated pharmaceutical company listed on the Nasdaq Capital Market under the ticker AYTU, disclosed in an SEC filing on November 16, 2026 that it had signed an Agreement and Plan of Merger with Rosemont Pharmaceuticals Holdings, Inc. and RoseApollo Merger Sub, Inc., a wholly owned subsidiary of Rosemont.
Under the agreement, Rosemont's subsidiary will launch a tender offer for all outstanding Aytu common stock at $2.70 per share in cash, net to the seller and without interest, subject to tax withholding. The filing says the offer is to begin no later than ten business days after the agreement date and is scheduled to expire on the twentieth day after it starts, unless extended.
Aytu's board and a special committee of the board unanimously recommended that stockholders accept the offer and tender their shares.
Aytu shares closed at $2.66 on the day, up 46.15% from the prior close of $1.82, according to the price data. Volume was 4,434,500 shares against an average of 57,372 — about 77 times normal.
The deal terms
Rosemont's obligation to complete the offer depends on a majority of Aytu's outstanding shares being validly tendered and not withdrawn, counting shares Rosemont and its subsidiaries already own. The offer is not conditioned on financing.
Other conditions in the filing include the accuracy of Aytu's representations and warranties subject to materiality standards, Aytu's material compliance with its covenants, the absence of a material adverse effect on Aytu, receipt of required third-party consents, and receipt of customary payoff letters for outstanding debt defined in the agreement as Payoff Debt.
There is also a condition on Aytu's warrants: no more than 15% of the warrants, measured by the number of underlying shares, may remain outstanding unexercised at the offer's expiration date without having been exercised and tendered under a warrant exercise agreement, or terminated under a support agreement or warrant termination agreement.
After the tender offer closes, the parties plan a second-step merger under Section 251(h) of Delaware corporate law, which allows a merger to be completed without a separate stockholder vote once a majority stake has been acquired in the offer. Aytu would become a wholly owned subsidiary of Rosemont.
The agreement can be terminated by either party if the offer is not completed by February 14, 2027. Aytu would owe Rosemont a $2.4 million termination fee in specified circumstances, including terminating to accept a superior proposal or if Rosemont terminates after the board withdraws its recommendation.
Equity awards and warrants
The filing sets out how stock options, restricted shares and warrants are handled. Options that are unvested become fully vested immediately before the merger closes and are cancelled in exchange for a cash payment equal to the number of underlying shares times the amount by which the $2.70 merger consideration exceeds the option's exercise price. Options with an exercise price at or above $2.70 are cancelled for no consideration, after holders get at least ten days to exercise them.
Restricted shares become free of vesting and forfeiture restrictions and are treated as shares. Equity plans and the employee stock purchase plan are terminated at the closing.
Aytu is required to use reasonable best efforts to get warrant holders who are not party to support agreements to either exercise their warrants or sign termination agreements before the deadline. Warrants covered by a support agreement or termination agreement are cancelled just before closing for the cash amount specified in that agreement; any other outstanding warrant is handled according to its own terms.
The filing says certain officers, all directors and certain stockholders signed tender and support agreements with Rosemont and its subsidiary, agreeing to tender their shares and to terminate their warrants at closing.
What this means
The filing is a Form 425, which companies file when they are in a merger or acquisition and are communicating about it. It is a disclosure document, not a vote: it puts the deal terms, the conditions and the termination provisions on the public record so stockholders can see them before deciding whether to tender.
A tender offer is a public invitation to all shareholders to sell their shares at a stated price for a set period. Here the price is $2.70 in cash, fixed. The filing notes that the offer itself has not started; Rosemont's subsidiary will file a Tender Offer Statement on Schedule TO with the offer documents, and Aytu will file a Schedule 14D-9 giving its recommendation. Those documents are the ones shareholders receive.
The mechanics matter because the deal is structured in two steps. The tender offer gets Rosemont past a majority stake without a stockholder meeting; Section 251(h) of the Delaware General Corporation Law then lets the remaining shares be bought out in a short-form merger at the same $2.70 price. Because the board has already recommended the offer, the filing's practical effect is to put a fixed cash price in front of stockholders and set a timetable for them to accept it.
The $2.66 closing price on the day was 4 cents below the offer price, a small gap that reflects, among other things, the conditions still outstanding — the majority tender threshold, third-party consents, debt payoff letters and the warrant condition — and the time until the offer closes. The filing does not say why Rosemont is buying Aytu or what it plans to do with the business.
Sources
- Daily price and volume history
- 425 filed 2026-11-16
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.